Full Press Release Details
Melbourne (Australia) | 8 January 2024
Telix today advises it is presenting at the 42 nd Annual J.P. Morgan Healthcare Conference (8-11 January 2024) in San Francisco.
As part of the Company’s presentation (lodged with this announcement), Telix has provided an update on unaudited revenue for Q4 2023, with the Company reporting $148.1M (US$97.1M [1] ) of total product revenue, primarily generated from sales of Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) in the United States. This is an increase of 11% on the prior quarter (Q3 2023) revenue of $133.6M (US$87.2M [2] ). The total revenue (unaudited) for FY 2023 is $502.5M (US$333.0M [3] ).
Group CEO and Managing Director, Dr. Christian Behrenbruch stated, “We are delighted to be providing an update for investors at this leading global investment conference. In addition to showcasing the continued strong commercial performance of Illuccix, which is generating significant revenue, we will share an update of progress across the pipeline as we advance multiple late-stage therapeutic programs, prepare to bring two additional imaging agents to market and continue the vertical integration of supply and manufacturing.”
The presentation will take place on Tuesday 9 January at 3:00pm PST (6:00pm EST / 10:00am AEDT 10 January).
Participants can register for the webcast at the following link .
Telix expects to report its full year financial results for the year ended 31 December 2023 on Thursday 22 February 2024.
To read the full presentation click here
[1] Conversion to AUD$ is at an average exchange rate realised during Q4 2023 of AUD$1 = US$0.656
[2] Conversion to AUD$ is at an average exchange rate realised during Q3 2023 of AUD$1 = US$0.652
[3] Conversion to AUD$ is at an average exchange rate realised during the year of AUD$1 = US$0.663